Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus MERILOG SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus MERILOG SOLOSTAR.
HUMALOG MIX 50/50 KWIKPEN vs MERILOG SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
0.5 mg subcutaneously once a day.
None Documented
None Documented
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Category C
Category C
Insulin
Insulin